Avidity Biosciences Inc (NASDAQ: RNA) on Friday, soared 3.19% from the previous trading day, before settling in for the closing price of $42.64. Within the past 52 weeks, RNA’s price has moved between $4.82 and $48.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 148.90% over the last five years. The company achieved an average annual earnings per share of -0.07%. With a float of $108.77 million, this company’s outstanding shares have now reached $117.12 million.
The firm has a total of 253 workers. Let’s measure their productivity. In terms of profitability, gross margin is 69.4%, operating margin of -2690.64%, and the pretax margin is -2381.82%.
Avidity Biosciences Inc (RNA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Avidity Biosciences Inc is 8.73%, while institutional ownership is 93.19%. The most recent insider transaction that took place on Aug 19 ’24, was worth 225,946. In this transaction Director of this company sold 5,000 shares at a rate of $45.19, taking the stock ownership to the 14,830 shares. Before that another transaction happened on Aug 06 ’24, when Company’s President and CEO sold 28,000 for $43.35, making the entire transaction worth $1,213,822. This insider now owns 205,043 shares in total.
Avidity Biosciences Inc (RNA) Earnings and Forecasts
As on 6/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.71 earnings per share (EPS) for the period topping the consensus outlook (set at -0.77) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.79 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -0.07% per share during the next fiscal year.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Avidity Biosciences Inc (RNA) is currently performing well based on its current performance indicators. A quick ratio of 15.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 486.16.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.95, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -3.12 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Analysing the last 5-days average volume posted by the [Avidity Biosciences Inc, RNA], we can find that recorded value of 0.7 million was lower than the volume posted last year of 1.33 million. As of the previous 9 days, the stock’s Stochastic %D was 29.32%. Additionally, its Average True Range was 2.35.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 81.92%, which indicates a significant increase from 63.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.40% in the past 14 days, which was lower than the 71.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $43.29, while its 200-day Moving Average is $24.67. Now, the first resistance to watch is $44.97. This is followed by the second major resistance level at $45.94. The third major resistance level sits at $47.27. If the price goes on to break the first support level at $42.67, it is likely to go to the next support level at $41.34. Should the price break the second support level, the third support level stands at $40.37.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
Market capitalization of the company is 5.15 billion based on 95,637K outstanding shares. Right now, sales total 9,560 K and income totals -212,220 K. The company made 2,050 K in profit during its latest quarter, and -70,790 K in sales during its previous quarter.
